Roth MKM keeps a Buy rating and $7 price target on Gain Therapeutics (GANX) after the company received approval from Australian regulators to begin GT-02287 evaluation in Parkinson’s disease patients. The firm believes that the Phase 1b study will deliver positive findings regarding safety, preliminary biochemical efficacy, and tolerability, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas” class=”link “>Try Now>>
Read More on GANX:
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email news@emeatribune.com Follow our WhatsApp verified Channel
